# Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Canonical URL: https://biopharmsignal.com/news/NKTX/nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights
Ticker: NKTX
Company: Nkarta
Source: Nkarta
Published: 2026-05-12 20:01 EST
Original Source URL: https://ir.nkartatx.com
## Summary

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2

## Article Body
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2
## Recent Company News
- 2026-05-12 20:01 EST — [Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/NKTX/nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Nkarta
- 2026-04-15 20:01 EST — [Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers](https://biopharmsignal.com/news/NKTX/nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers) — Source: Nkarta
- 2026-04-09 11:00 EST — [Nkarta to Participate in Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-needham-virtual-healthcare-conference) — Source: Nkarta
- 2026-03-25 20:01 EST — [Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights) — Source: Nkarta
- 2026-02-27 13:00 EST — [Nkarta to Participate in March Investor Conferences](https://biopharmsignal.com/news/NKTX/nkarta-to-participate-in-march-investor-conferences) — Source: Nkarta
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)